Trust Signals
Written by the FormBlends Medical Team. All claims are graded by evidence type in the ledger below. No claim is presented with higher confidence than the data supports. Real trial names and authors are cited where available. Speculative claims are labeled as such.
Key Takeaways
- Tesamorelin is the only FDA-approved compound of the three, indicated at 2 mg/day subcutaneously for HIV-associated lipodystrophy, with Phase 3 data showing roughly 15 to 18% visceral fat reduction over 26 weeks (Falutz et al., 2007, 2010).
- Hexarelin acts on GHS-R1a receptors rather than GHRH receptors, producing GH release alongside measurable cortisol and prolactin elevation, a hormonal profile absent with sermorelin and tesamorelin.
- Sermorelin covers only residues 1 to 29 of native GHRH, giving it a shorter half-life (roughly 10 to 20 minutes in human studies) than tesamorelin, which carries a trans-3-hexenoic acid modification that extends its activity.
- Hexarelin demonstrates receptor desensitization (tachyphylaxis) with daily dosing in human PK/PD studies, making continuous uninterrupted use less practical than GHRH analog protocols.
- No large RCT in healthy, non-HIV adults has validated body composition superiority for any of the three peptides, so extrapolation from approved indications requires Low to Very Low confidence ratings.
Which is better: hexarelin, sermorelin, or tesamorelin?
Tesamorelin wins on regulatory standing and human evidence. Sermorelin is the most permissive regulatory entry point but has the weakest modern clinical dataset. Hexarelin occupies a distinct pharmacological niche as a ghrelin-receptor agonist with cardiac and cortisol effects not shared by the others. The right choice depends on indication, risk tolerance, and the evidence standard you require.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- How do the three mechanisms actually differ?
- Evidence ledger: what does the human data actually show?
- Mechanism with numbers: receptors, half-lives, and GH pulse data
- What most comparison pages get wrong
- Honest head-to-head table
- Stability, formulation, and sourcing realities
- Dosing and label literacy: how to read a protocol or COA
- How do these compare to approved alternatives like recombinant GH?
- Side effect profiles compared
- FAQ
- Sources
How do the three mechanisms actually differ?
Sermorelin and tesamorelin are both GHRH analogs. They bind the pituitary GHRH receptor (GHRHR), a G-protein coupled receptor that activates adenylyl cyclase, raises intracellular cAMP, and drives somatotroph cells to release GH. The released GH then stimulates hepatic IGF-1 production, which mediates downstream anabolic and lipolytic effects.
Sermorelin covers the first 29 amino acids of native 44-residue GHRH. This truncated sequence retains full agonist activity at the GHRHR but loses the structural stability of the full-length molecule. Tesamorelin is full-length GHRH (1 to 44) conjugated at its N-terminus to trans-3-hexenoic acid. That lipophilic modification increases resistance to dipeptidyl peptidase IV (DPP-IV) cleavage, the primary degradation pathway for GHRH analogs in plasma, meaningfully extending its biological activity.
Hexarelin is a synthetic hexapeptide (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) that acts as an agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), the endogenous ghrelin receptor. This is a structurally and pharmacologically distinct receptor from GHRHR. GHS-R1a activation stimulates GH release through a different intracellular pathway (phospholipase C, IP3/DAG) and also activates GHS-R1a expressed on corticotrophs and lactotrophs, explaining co-secretion of ACTH/cortisol and prolactin. Hexarelin also has documented cardioprotective activity in animal models through a GHS-R1a-independent cardiac receptor, though human translation of this effect is not established.
Evidence ledger: what does the human data actually show?
| Claim | Compound | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|---|
| Reduces visceral fat in HIV lipodystrophy | Tesamorelin | 2 Phase 3 RCTs (Falutz et al., 2007, 2010; n roughly 400 each) | Roughly 15 to 18% VAT reduction at 26 weeks | High (for this indication) |
| Raises serum IGF-1 | Tesamorelin | Phase 3 RCT | Significant increase vs placebo | High |
| Raises GH in GH-deficient adults | Sermorelin | Small RCTs and open-label human studies | Positive, dose-dependent | Moderate |
| Stimulates GH pulse in healthy adults | Hexarelin | Short-term human PK/PD studies (Ghigo et al., 1994) | Positive, attenuates with repeat dosing | Moderate (for acute effect), Low (for sustained outcomes) |
| Elevates cortisol and prolactin | Hexarelin | Human PK/PD studies | Positive co-secretion documented | Moderate |
| Cardioprotective effect in humans | Hexarelin | Animal models only; no large human RCT | Positive in rodent models | Very Low |
| Body composition improvement in healthy non-HIV adults | All three | No large human RCT for any | Speculative extrapolation | Very Low |
| Improves lipid profiles in HIV lipodystrophy | Tesamorelin | Phase 3 RCT secondary endpoints | Modest triglyceride reduction seen | Moderate |
Mechanism with numbers: receptors, half-lives, and GH pulse data
Half-lives: Sermorelin has a plasma half-life of roughly 10 to 20 minutes in human studies, driven by rapid DPP-IV cleavage at the N-terminal Tyr-Ala bond. Tesamorelin's trans-3-hexenoic acid modification blocks this cleavage site, extending its half-life and duration of pituitary stimulation, though the exact human half-life figure varies across studies and no single canonical value should be cited without the source. Hexarelin has a similarly short plasma half-life, consistent with other small synthetic peptides, but its receptor binding characteristics differ from GHRH analogs.
GH pulse magnitude: Ghigo et al. (1994) showed that hexarelin at 2 mcg/kg IV produced GH peaks in healthy adults exceeding those seen with GHRH alone, and that combining hexarelin with GHRH produced synergistic GH release greater than either alone. This is the mechanistic basis for GHRP plus GHRH combination protocols. However, the same group documented that daily hexarelin administration over two weeks produced blunted GH responses, consistent with GHS-R1a desensitization.
Tesamorelin Phase 3 data: The pivotal trials by Falutz et al. (published in the New England Journal of Medicine, 2007, and Journal of Acquired Immune Deficiency Syndromes, 2010) enrolled HIV-positive patients on stable antiretroviral therapy with CT-confirmed visceral adiposity. At 2 mg/day subcutaneously over 26 weeks, the tesamorelin group showed roughly 15 to 18% reduction in visceral adipose tissue measured by CT scan versus placebo. Effects on subcutaneous fat were smaller and less consistent. Effects were largely reversed within 12 weeks of discontinuation, demonstrating that tesamorelin suppresses visceral fat accumulation rather than permanently resetting fat distribution.
What these numbers do not prove: GH pulse magnitude does not translate linearly to anabolic or lipolytic outcomes. A larger acute GH spike from hexarelin does not establish superior body composition outcomes compared to sustained, lower-amplitude GH release from a GHRH analog. The correlation between single-injection IGF-1 changes and months-long body composition shifts requires its own evidence layer, which exists only for tesamorelin in the HIV context.
What most comparison pages get wrong
Most pages treat these three as interchangeable "GH peptides" varying only in potency. That framing misses three critical distinctions.
Receptor class is not trivial. Hexarelin's GHS-R1a activity means it activates a different intracellular signaling cascade, stimulates ACTH and prolactin co-secretion, and has known tachyphylaxis kinetics. Treating it as a "stronger sermorelin" is pharmacologically wrong.
Regulatory and sourcing reality. Tesamorelin (Egrifta, Egrifta SV) is an FDA-approved drug with a manufacturing standard. Sermorelin compounded formulations are subject to shifting FDA guidance on which peptides may be compounded. Hexarelin has no approved drug product in the United States and is available only as a research chemical or through compounding in certain jurisdictions. The quality gap between an approved drug and a research-grade peptide is not theoretical: independent testing of research peptides frequently finds purity below labeled claims and sequence errors in smaller batches.
The "natural GH axis" argument is overstated. GHRH analogs are often marketed as safer because they "work with the axis." They do preserve pulsatility better than exogenous GH. But tesamorelin still suppresses endogenous GHRH feedback and raises IGF-1, and prolonged GHRH receptor stimulation is not without physiological consequence. The FDA label for tesamorelin carries warnings about glucose metabolism impairment and potential neoplastic disease risk consistent with elevated IGF-1.
Honest head-to-head table
| Parameter | Hexarelin | Sermorelin | Tesamorelin |
|---|---|---|---|
| Receptor target | GHS-R1a (ghrelin receptor) | GHRHR | GHRHR |
| FDA approval status | None | None (branded Geref discontinued) | Approved (Egrifta, HIV lipodystrophy) |
| Human RCT evidence for body composition | Very Low (no large RCT) | Low to Moderate (GH deficiency only) | High (for HIV VAT); Very Low for healthy adults |
| Cortisol/prolactin elevation | Yes, documented in human studies | Minimal | Minimal |
| Tachyphylaxis risk | High with daily use | Low to moderate | Low to moderate |
| Stability advantage | None notable | Lower stability (shorter sequence) | Better stability (lipid modification) |
| Synergy with GHRH analogs | Yes (different receptor) | No meaningful synergy with tesamorelin | No meaningful synergy with sermorelin |
| Glucose metabolism warning | Theoretical via GH/IGF-1 | Theoretical via GH/IGF-1 | FDA label warning; documented in Phase 3 |
| Where the peptide LOSES | Loses on hormonal side-effect profile and desensitization vs GHRH analogs | Loses on half-life, stability, and evidence base vs tesamorelin | Loses on cost and accessibility vs compounded alternatives; no data in healthy adults |
| WADA prohibited | Yes | Yes | Yes |
Stability, formulation, and sourcing realities
All three peptides are supplied as lyophilized (freeze-dried) powder because the hydrated forms degrade too rapidly for practical storage. Understanding why matters for anyone evaluating a product or protocol.
Oxidation of methionine residues. Sermorelin and hexarelin contain tryptophan residues that are susceptible to oxidative degradation, particularly under UV light and at elevated temperatures. Tesamorelin contains methionine at position 27, a well-characterized oxidation hotspot in GHRH peptides. Oxidized methionine converts to methionine sulfoxide, which can reduce receptor binding affinity and biological activity without visibly changing the vial appearance. This is why storing peptides in dark, refrigerated conditions is not a marketing preference but a chemistry necessity. A product left at room temperature for days may retain appearance while losing meaningful potency.
Hydrolysis after reconstitution. Once reconstituted, peptide bonds are subject to hydrolysis, particularly at aspartate residues under acidic or basic pH conditions. Bacteriostatic water (containing 0.9% benzyl alcohol) is preferred over plain sterile water for multi-dose vials because it slows microbial growth that could accelerate degradation, and it maintains near-neutral pH. Repeated freeze-thaw cycles stress the peptide backbone and should be avoided.
The COA you should demand. Any legitimate peptide product should be accompanied by a Certificate of Analysis from an accredited third-party laboratory. Look for: HPLC purity above 98%, mass spectrometry confirmation of the correct molecular weight (hexarelin MW roughly 887 Da, sermorelin MW roughly 3358 Da, tesamorelin MW roughly 5135 Da), and absence of residual solvents. A COA generated by the same company selling the product is not independent verification.
Research chemical vs. compounded medication. Research-grade hexarelin sold online as "not for human use" bypasses the manufacturing standards applied to compounded medications. Independent testing by organizations that have assessed research peptide markets consistently finds a meaningful proportion of samples with purity below labeled claims or wrong sequences. This is the highest-stakes sourcing distinction in this market.
Dosing and label literacy: how to read a protocol or COA
| Compound | FDA-Approved Dose (if applicable) | Common Investigational Range | Route | Frequency Note |
|---|---|---|---|---|
| Tesamorelin | 2 mg/day SC (HIV lipodystrophy) | Same as approved; off-label use unstudied at other doses | Subcutaneous injection | Once daily, consistent timing |
| Sermorelin | No current approved product | 100 to 500 mcg per injection in adult compounding protocols | Subcutaneous injection | Often dosed at bedtime to align with endogenous GH pulsatility |
| Hexarelin | None | 100 to 200 mcg per injection in research protocols | Subcutaneous or intramuscular | Cycle use recommended due to tachyphylaxis; 4 to 6 week cycles with breaks cited in the literature |
Reconstitution math example for hexarelin at 2 mg/vial: Add 2 mL bacteriostatic water to yield a concentration of 1 mg/mL (1000 mcg/mL). A 100 mcg dose requires 0.1 mL drawn into a U-100 insulin syringe, which corresponds to the 10-unit mark. Verify this calculation independently before any use.
Reading the label: Confirm the peptide sequence or molecular weight on the COA matches published references. "Sermorelin acetate" and "sermorelin" refer to the same peptide; the acetate salt designation relates to formulation, not sequence. A label stating only "growth hormone releasing peptide" without a sequence or molecular weight confirmation is insufficient.
How do these compare to approved alternatives like recombinant GH?
| Parameter | GHRH Analogs / GHRPs | Recombinant Human GH (rhGH) |
|---|---|---|
| GH pulsatility preserved | Yes (stimulate endogenous release) | No (constant supraphysiologic levels) |
| IGF-1 elevation magnitude | Moderate, dose-dependent | Larger, dose-dependent |
| FDA approval for GH deficiency | No (tesamorelin only for HIV VAT) | Yes, multiple branded products |
| Fluid retention / edema risk | Lower (less supraphysiologic GH) | Higher at typical doses |
| Cost (approximate, US market) | Lower for compounded sermorelin; Egrifta is expensive | Very high for approved rhGH |
| Evidence for bone density | Indirect via IGF-1; not directly studied at scale | Moderate human evidence in GH deficiency |
Side effect profiles compared
Tesamorelin (from FDA label and Phase 3 data): The most common adverse effects in the pivotal trials included injection site reactions, arthralgia, peripheral edema, and myalgia. Glucose intolerance and new-onset diabetes were observed at a higher rate in the tesamorelin group versus placebo, consistent with GH-mediated insulin antagonism. The label carries precautions regarding active malignancy and IGF-1 elevation. Patients with diabetes or prediabetes require closer glucose monitoring.
Sermorelin: Generally well tolerated in published compounding-era studies. Injection site reactions are the most common complaint. Flushing, dizziness, and headache have been reported. Because it stimulates endogenous GH rather than replacing it, the ceiling effect of pituitary reserve limits the degree of supraphysiologic GH elevation and blunts many dose-dependent side effects seen with rhGH.
Hexarelin: Beyond the documented cortisol and prolactin co-elevation, water retention and increased appetite (via the ghrelin receptor pathway) have been reported in human studies. The tachyphylaxis pattern and the cortisol elevation distinguish its risk profile from GHRH analogs. The cardiac effects seen in animal models have not been reproduced or characterized sufficiently in humans to draw clinical conclusions in either direction.
FAQ
What is the main difference between hexarelin, sermorelin, and tesamorelin?
Hexarelin is a ghrelin-receptor agonist (GHRP) that stimulates GH release via GHS-R1a and also elevates cortisol and prolactin. Sermorelin is a GHRH analog covering residues 1 to 29 of native GHRH with a short half-life of roughly 10 to 20 minutes. Tesamorelin is a stabilized full-length GHRH analog with the strongest human RCT evidence base, including FDA approval for HIV-associated lipodystrophy.
Which has the strongest human evidence: hexarelin, sermorelin, or tesamorelin?
Tesamorelin has the strongest evidence by a wide margin. It is the only one FDA-approved, supported by two Phase 3 RCTs in HIV-lipodystrophy patients showing roughly 15 to 18% visceral fat reduction over 26 weeks. Sermorelin has moderate human data mostly from GH-deficient pediatric and adult studies. Hexarelin has mostly short-term human PK/PD data and animal studies for cardiac effects.
Does hexarelin raise cortisol and prolactin?
Yes. Hexarelin stimulates GHS-R1a receptors in the pituitary and hypothalamus, activating pathways beyond pure somatotrophs, leading to measurable cortisol and prolactin elevations in human studies. This is a meaningful clinical distinction from sermorelin and tesamorelin, which act primarily through GHRH receptors without the same hormonal co-activation.
Is sermorelin still available by prescription?
The original branded sermorelin acetate (Geref) was discontinued by the manufacturer. Sermorelin is available only through compounding pharmacies in the United States. FDA has categorized it as a substance subject to compounding restrictions, so availability depends on current regulatory status and the specific pharmacy.
What dose of tesamorelin is used in FDA-approved protocols?
The FDA-approved dose of tesamorelin (Egrifta) for HIV-associated lipodystrophy is 2 mg subcutaneously once daily. This dose was used in the pivotal Phase 3 trials. Off-label compounded use at lower doses has not been validated in large RCTs.
Does hexarelin desensitize GH receptors with repeated dosing?
Yes. Human pharmacodynamic studies have shown that GH pulse amplitude from hexarelin attenuates with repeated daily dosing, consistent with GHS-R1a downregulation. This tachyphylaxis is more pronounced than with GHRH analogs like sermorelin and tesamorelin, which is a practical reason to cycle hexarelin.
Can you combine any of these peptides with each other?
Hexarelin is sometimes combined with GHRH analogs because GHRPs and GHRH act on different receptors and show synergistic GH release in pharmacodynamic studies. Combining two GHRH analogs (sermorelin plus tesamorelin) is not logical as they compete for the same receptor without added synergy. No large human RCT has validated combination protocols for body composition outcomes.
How stable are these peptides after reconstitution?
All three are lyophilized peptides that degrade meaningfully after reconstitution. General peptide chemistry guidance supports refrigerated storage in bacteriostatic water and use within a few weeks of reconstitution. Heat, repeated freeze-thaw cycles, and acidic or basic pH accelerate hydrolysis and oxidation of vulnerable residues. Tryptophan and methionine residues in these sequences are particularly susceptible.
Which peptide is best for body composition in non-HIV adults?
There is no large RCT establishing superiority in healthy, non-HIV adults for any of the three. Tesamorelin has the best mechanistic case given proven visceral fat reduction via GH-IGF-1 axis activation, but its evidence base is specifically in HIV lipodystrophy. Extrapolating those results to healthy adults requires Low to Very Low evidence confidence.
Are any of these peptides on the WADA prohibited list?
Yes. WADA prohibits peptide hormones and their releasing factors both in competition and out of competition. All three fall under this category as GH secretagogues or GHRH analogs. Athletes subject to anti-doping rules should not use any of them.
What does a degraded or counterfeit vial of these peptides look like?
Legitimate lyophilized peptides appear as a white to off-white cake or powder. A degraded or poorly manufactured vial may show discoloration, visible particulates after reconstitution, or loss of the expected vacuum seal. An authentic COA from an accredited lab should confirm purity above 98% by HPLC and mass confirmation of the correct molecular weight.
Sources
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
- Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes. 2010;53(3):311-322.
- Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. European Journal of Endocrinology. 1997;136(5):445-460.
- Ghigo E, Arvat E, Rizzi G, et al. Arginine enhances the growth hormone (GH)-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration. Journal of Endocrinological Investigation. 1994;17(3):157-162.
- Popovic V, Damjanovic S, Micic D, et al. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamo-pituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. Journal of Clinical Endocrinology and Metabolism. 1995;80(3):942-947.
- U.S. Food and Drug Administration. Egrifta (tesamorelin for injection) Prescribing Information. FDA.gov. Accessed 2026.
- Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective GH-receptor antagonist, pegvisomant (B2036-PEG), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. Journal of Clinical Endocrinology and Metabolism. 2001;86(7):3304-3310.
- World Anti-Doping Agency (WADA). Prohibited List 2024. WADA-AMA.org. Accessed 2026.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308.
- Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545.
Research Snapshot
Head-to-head comparisonEntities covered
Provider pricing, medication availability, pharmacy partners, insurance support, and cancellation rules can change quickly. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-05-30.
Evidence standard
How this page was source-checked
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
PubMed evidence trail
Research sources used to frame this page
For Hexarelin vs Sermorelin vs Tesamorelin: Which GH Peptide Wins? | FormBlends, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin
Supports mechanism-level discussion while keeping evidence limits visible.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
Hexarelin vs Sermorelin vs Tesamorelin: Which GH Peptide Wins? should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Original tools and data
Use the FormBlends research stack
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Editorial refresh
Practical 2026 note for Hexarelin vs Sermorelin vs Tesamorelin
Hexarelin vs Sermorelin vs Tesamorelin now carries extra 2026 context around cash-pay pricing, safety signals, compare, hexarelin, sermorelin, tesamorelin, because those are the subtopics readers tend to compare before they trust a medical or wellness recommendation.
Instead of adding filler, this page keeps the named treatment terms, practical verification points, and next-step questions close to compare hexarelin vs sermorelin vs tesamorelin.
Readers should use the section to check current eligibility, pharmacy or provider policies, and safety questions with a licensed professional before acting.
Custom 2026 image for Hexarelin vs Sermorelin vs Tesamorelin, peptide therapy, and better treatment decision-making.
Download the Peptide Quick Reference Card
A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.
Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.
Written by the FormBlends Medical Team. All claims are graded by evidence type in the ledger below. No claim is presented with higher confidence than the data supports. Real trial names and authors are cited where available. Speculative claims are labeled as such.
Medical content team. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by FormBlends Medical Content Team for medical accuracy, sourcing, and patient-safety framing.